Knockout of B2M in combination with PD-L1 overexpression protects MSC-derived new islet β cells from graft rejection in the treatment of canine diabetes mellitus.

Publisher: BioMed Central Country of Publication: England NLM ID: 101527581 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-6512 (Electronic) Linking ISSN: 17576512 NLM ISO Abbreviation: Stem Cell Res Ther Subsets: MEDLINE

Original Publication: London : BioMed Central

Mesenchymal Stem Cells*/metabolism ; Mesenchymal Stem Cells*/cytology ; Insulin-Secreting Cells*/metabolism ; Insulin-Secreting Cells*/cytology ; Graft Rejection*/immunology ; B7-H1 Antigen*/metabolism ; B7-H1 Antigen*/genetics ; Mesenchymal Stem Cell Transplantation*/methods; Animals ; Dogs ; Cell Differentiation ; Diabetes Mellitus, Experimental/therapy ; Diabetes Mellitus/therapy

Background: The immunogenicity of allogeneic mesenchymal stem cells (MSCs) is significantly enhanced after transplantation or differentiation, and these cells can be recognized and cleared by recipient immune cells. Graft rejection has become a major obstacle to improving the therapeutic effect of allogeneic MSCs or, after their differentiation, transplantation in the treatment of diabetes and other diseases. Solving this problem is helpful for prolonging the time that cells play a role in the recipient body and for significantly improving the clinical therapeutic effect.
Methods: In this study, canine adipose-derived mesenchymal stem cells (ADSCs) were used as seed cells, and gene editing technology was used to knock out the B2M gene in these cells and cooperate with the overexpression of the PD-L1 gene. Gene-edited ADSCs (GeADSCs), whose biological characteristics and safety are not different from those of normal canine ADSCs, have been obtained.
Results: The immunogenicity of GeADSCs is reduced, the immune escape ability of GeADSCs is enhanced, and GeADSCs can remain in the body for a longer time. Using the optimized induction program, the efficiency of the differentiation of GeADSCs into new islet β-cells was increased, and the maturity of the new islet β-cells was increased. The immunogenicity of new islet β-cells decreased, and their immune escape ability was enhanced after the cells were transplanted into diabetic dogs (the graft site was prevascularized by the implantation of a scaffold to form a vascularized pouch). The number of infiltrating immune cells and the content of immune factors were decreased at the graft site.
Conclusions: New islet β-cell transplantation, which has low immunogenicity, can reverse diabetes in dogs, and the therapeutic effect of cell transplantation is significantly enhanced. This study provides a new method for prolonging the survival and functional time of cells in transplant recipients and significantly improving the clinical therapeutic effect.
Competing Interests: Declarations. Ethics approval and consent to participate: The study is reported in accordance with ARRIVE guidelines ( https://arriveguidelines.org ). All of the dogs were reared, obtained, and housed in accordance with our institute’s laboratory animal requirements. All procedures and the study design were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Ministry of Science and Technology of China, 2006) and were approved by the Animal Ethical and Welfare Committee of Northwest Agriculture and Forest University (Title of the approved project: Study on anti-graft rejection effect and mechanism of canine gene-edited MSCs and their differentiated cells. Date of approval: September 17, 2022. Approval No: 20220182). No human cells/tissues/samples/cell lines were used in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)

J Clin Med. 2019 Feb 15;8(2):. (PMID: 30781427)
Front Cell Dev Biol. 2021 Jun 28;9:685494. (PMID: 34262902)
Stem Cell Res Ther. 2022 Jul 28;13(1):370. (PMID: 35902971)
Biomater Adv. 2023 Jun;149:213389. (PMID: 36965402)
Transplantation. 2018 Jun;102(6):945-952. (PMID: 29521877)
Stem Cell Res Ther. 2020 Feb 7;11(1):52. (PMID: 32028995)
Cell Rep. 2021 Aug 17;36(7):109538. (PMID: 34407395)
Int J Mol Sci. 2022 Sep 02;23(17):. (PMID: 36077421)
bioRxiv. 2024 Apr 29;:. (PMID: 38746298)
FEBS Open Bio. 2018 Feb 05;8(3):372-382. (PMID: 29511614)
Anim Biosci. 2024 Sep;37(9):1503-1516. (PMID: 38754850)
Sci Rep. 2019 Dec 10;9(1):18731. (PMID: 31822724)
J Surg Res. 2013 May 1;181(1):146-55. (PMID: 22683077)
Cancer Lett. 2021 Oct 1;517:96-104. (PMID: 34129878)
Blood Adv. 2024 Feb 13;8(3):581-590. (PMID: 38052043)
Life Sci. 2024 Jul 15;349:122722. (PMID: 38754814)
Diabetes Care. 2016 Jun;39(6):1060-4. (PMID: 27208324)
Science. 2001 May 18;292(5520):1389-94. (PMID: 11326082)
Cell. 2014 Oct 9;159(2):428-39. (PMID: 25303535)
Sci Adv. 2021 Jul 2;7(27):. (PMID: 34215590)
Front Endocrinol (Lausanne). 2021 Aug 10;12:716625. (PMID: 34447354)
Sci Rep. 2024 Mar 28;14(1):7451. (PMID: 38548796)
Front Immunol. 2019 Apr 03;10:694. (PMID: 31001285)
Nat Biotechnol. 2018 Jun;36(5):411-420. (PMID: 29608179)
Biol Chem. 2021 Feb 05;402(6):693-702. (PMID: 33544464)
Front Endocrinol (Lausanne). 2021 Jul 09;12:707881. (PMID: 34305820)
Stem Cells. 2009 Nov;27(11):2865-74. (PMID: 19750539)
PeerJ. 2024 Mar 28;12:e17184. (PMID: 38560451)
Cell Stem Cell. 2022 Nov 3;29(11):1515-1530. (PMID: 36332569)
Cell J. 2020 Jan;21(4):371-378. (PMID: 31376318)
Heliyon. 2020 May 05;6(5):e03914. (PMID: 32395661)
Endocr Rev. 2019 Apr 1;40(2):631-668. (PMID: 30541144)
J Cancer. 2021 Mar 5;12(9):2735-2746. (PMID: 33854633)
Acta Pharmacol Sin. 2023 Feb;44(2):268-287. (PMID: 35896695)
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4. (PMID: 18077471)
Equine Vet J. 2017 Jul;49(4):539-544. (PMID: 27862236)
Cardiovasc Diabetol. 2024 Apr 25;23(1):139. (PMID: 38664790)
Biomater Sci. 2020 Jan 21;8(2):631-647. (PMID: 31729495)
Exp Ther Med. 2019 Oct;18(4):2592-2598. (PMID: 31572507)
Clin Exp Immunol. 2010 Oct;162(1):91-9. (PMID: 20726990)
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8741-8750. (PMID: 31696460)

K3031223086 2023 Animal Epidemic Prevention project; 2023BSHEDZZ144 Shaanxi Province postdoctoral research project second-class funding

Keywords: Antigraft rejection; Gene-edited ADSCs; Immunogenicity; New islet β cells; Therapeutic effect

0 (B7-H1 Antigen)

Date Created: 20241202 Date Completed: 20241203 Latest Revision: 20241205

20241209

PMC11613808

10.1186/s13287-024-04067-7

39623490